Fundraising FoxSamsara BioCapital — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in
BoardJill Carroll(Director)inTiba Aynechi(Director)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RA CapitalSR One Capital ManagementAmgen VenturesLogosNorwest Venture Partners+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Chinook Therapeutics U.SNkarta TherapeuticsSpringWorks Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.